Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension

Abstract

Aims Nebivolol is a selective β1‐receptor antagonist with vasodilating properties. In patients with essential hypertension, we tested the hypothesis that nebivolol increases systemic and renal nitric oxide (NO) availability using L‐NG‐monomethyl arginine (L‐NMMA) as an inhibitor of NO production. Methods In a randomized, placebo‐controlled, crossover study, patients with essential hypertension were treated with nebivolol for five days, along with a standardized diet and fluid intake. We examined the acute effects of systemic NO synthase inhibition with L‐NMMA on brachial blood pressure (bBP), pulse wave velocity (PWV) and central blood pressure (cBP) estimated by applanation tonometry, glomerular filtration rate (GFR), fractional excretion of sodium (FENa), urinary excretion of both aquaporin‐2 (u‐AQP2) and epithelial sodium channels (u‐ENaCγ), and plasma concentrations of nitrate/nitrite (p‐NOx) and vasoactive hormones after five days' treatment with placebo and nebivolol. Results Nebivolol significantly reduced PWV, bBP, cBP and plasma renin, angiotensin II and aldosterone concentrations. The renal parameters, p‐NOx and plasma arginine vasopressin concentration were not changed by nebivolol. There was no difference between nebivolol and placebo in the response to L‐NMMA, with LMMA inducing a similar increase in PWV, bBP and cBP and a similar decrease in GFR, uAQP2 and u‐ENaCγ and FENa [mean change −0.62% (95% confidence interval {CI} −0.40 to −0.84) during placebo vs. −0.57% (95% CI −0.46 to −0.68; P = 0.564) during nebivolol treatment]. Vasoactive hormones were changed to a similar extend by L‐NMMA during administration of nebivolol and placebo. Conclusions Nebivolol did not change p‐NOx, and inhibition of NO synthesis induced the same response in blood pressure, GFR, renal tubular function and vasoactive hormones during nebivolol and placebo. Thus, the data did not support the hypothesis that nebivolol changes vascular and renal NO availability in patients with essential hypertension.

Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects – a randomized controlled trial

“…GFR was estimated using constant infusion clearance technique with 51 Cr-EDTA as reference marker. A GFR variation og 15% variation or more between the three baseline periods led to the exclusion of clearance related analysis [20, 22].…”

Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

“…Plasma osmolality was determined by using freeze-point depression (Multi-Sample Osmometer, Model 3900, Advanced Instruments, MA, USA). Urinary excretion rate of nitrate was determined by using a colorimetric assay using a kit from R&D Systems (Minneapolis, MN, USA) as previously decribed [ 31 ]. Sodium, albumin, hemoglobin, and glucose were measured by routine methods in Department of Clinical Biochemistry, Holstebro Hospital, Denmark.…”

Nebivolol Ameliorates Cisplatin‐Induced Nephrotoxicity in Rats

“…In the present study, nebivolol significantly decreased cisplatininduced increases in these mediators. Nebivolol significantly reduced plasma Ang II concentration in patients with essential hypertension [36] and spontaneously hypertensive rats [37]. Nebivolol, a selective b 1 -adrenoceptor antagonist, may reduce Ang II level via reduction of renin release [38].…”